Publications by authors named "M W Retter"

Claim this Profile
A
A TMPRSS6-inhibiting mAb improves disease in a β-thalassemia mouse model and reduces iron in healthy humans.
Heinrich E Lob, Nikhil Singh, Kusha Mohammadi, Larisa Ivanova, Beth Crowell, Marc W Retter

JCI Insight· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Industry Perspective on First-in-Human and Clinical Pharmacology Strategies to Support Clinical Development of T-Cell Engaging Bispecific Antibodies for Cancer Therapy.
Prathap Nagaraja Shastri, Nirav Shah, Martin Lechmann, Hardik Mody, Marc W Retter

Clin Pharmacol Ther· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Translational findings support regimen selection for first-in-human study of ubamatamab (MUC16 × CD3 bispecific antibody) in patients with recurrent ovarian cancer.
Min Zhu, Priyanka Madia, Alison Crawford, Jurriaan Brouwer-Visser, Pamela Krueger, Marc W Retter

Clin Transl Sci· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and pharmacodynamics of pozelimab alone or in combination with cemdisiran in non-human primates.
Kishor Devalaraja-Narashimha, Cong Huang, Marc Cao, Ya Ping Chen, Anna Borodovsky, Marc W Retter

PLoS One· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Translational findings for odronextamab: From preclinical research to a first-in-human study in patients with CD20+ B-cell malignancies.
Min Zhu, Kara Olson, Jessica R Kirshner, Masood Khaksar Toroghi, Hong Yan, Marc W Retter

Clin Transl Sci· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis